评论了期刊 2020-01-08
PLOS ONE
就是需要修改的意思186****8985暂无昵称 2020-01-08 00:00:00 发表:
请问大家这样代表啥意思?没有说是小修还是大修。
Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
You need to make methodology more clear and provide better presentation for the result section.
We would appreciate receiving your revised manuscript by Feb 20 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
评论了期刊 2019-11-27
DIABETES CARE
研究方向:糖尿病临床。 2019.11.20投稿,2019.11.25拒稿。 投稿时候,写了个cover letter:恳请编辑写清楚拒稿原因和建议。 确实写了一段原因和建议,大致是新意不够,潜在机制还需研究,估计是讨论写的不好。 就这么多吧,
评论了期刊 2019-11-21
CLIN ENDOCRINOL
啥原因?我也想投一篇糖尿病高血压的182W79f0175(暂无昵称) 2017-10-25 12:25:00 发表:
投了就一篇关于糖尿病高血压的文章,结果被秒拒了
评论了期刊 2019-11-16
BMC MED
按道理说不需要,临床研究首先是前瞻性研究,所以回顾性谈不上伦理wenzwl 2016-01-29 10:04:00 发表:
请问,如果是临床回顾性研究,在投稿的时候需要上传医学伦理批准文件吗?